THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN… SciBase announces outcome of rights issue of shares weiterlesen
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN… SciBase publishes prospectus in connection with fully guaranteed rights issue weiterlesen
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN… SciBase resolves on a fully guaranteed rights issue of approximately SEK 79.6 million weiterlesen
The ORIGINS Project follows the progress of pregnant women, their partners and babies for the first five years of the baby’s life, and beyond, based on an increasing understanding that an individual’s lifetime health and disease may be programmed at a very early stage – even while a child is still in the womb. The… Nevisense for skin barrier evaluation included in large Australian birth cohort study weiterlesen
The focus will be on SciBase’s recently announced collaboration with Johnson & Johnson Consumer Health to develop a unique AI-based screening tool to predict the development of a common type of eczema known as atopic dermatitis in infants. SciBase CEO Simon Grant will give an in-depth picture of the potential that exists in the skin… SciBase invitation to a webinar on November 10 at 11:00 CET weiterlesen
Link to press release from November 7th: http://investors.scibase.se/en/scibase-announces-collaboration-to-detect-skin-barrier-dysfunction-in-infants Simon Grant, CEO of SciBase comment on the skin barrier segment and the collaboration with Johnson & Johnson Consumer Health Inc. can be found through the link below: Link to CEO comment: https://players.brightcove.net/1555966121001/default_default/index.html?videoId=6315110856112 For more information around skin barrier and SciBase: https://barrier.scibase.com/ For more information, please contact:… SciBase CEO Simon Grant gives a comment regarding the collaboration with Johnson & Johnson Consumer Health weiterlesen
The goal of the collaboration is to develop and validate an AI-based solution that detects skin barrier dysfunction and may be able to predict an infant’s risk of developing atopic dermatitis. The method will be based on SciBase’s Electrical Impedance Spectroscopy (EIS) technology and specifically for the portable Nevisense Go device. The collaboration will start… SciBase announces collaboration to detect skin barrier dysfunction in infants weiterlesen
The article describes Electrical impedance spectroscopy (EIS) as a recently emerged promising alternative measurement of skin barrier function. EIS is a non-invasive indicator of epidermal integrity, rapidly measuring the skin’s resistance to the flow of alternating imperceptible currents. Considering the likely differences in cell size and orientation between typical and abnormal skin, EIS has been… New article discusses EIS as a potential clinical measure of skin barrier integrity weiterlesen
STOCKHOLM, SWEDEN, – October 26, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named “Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin… New study shows Nevisense significantly improves US clinician’s decision-making beyond dermoscopy weiterlesen
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 18, 2022. The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2023 in Stockholm. Shareholders who… The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2023: weiterlesen
